Loading data for XGN — first visit, this takes a few seconds.
Exagen Inc. (XGN)
NasdaqGM: XGN
· Real-Time Price · USD
7.58
+0.04 (0.53%)
At close: Sep 04, 2026, 8:00 PM
7.73
+1.98%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
Exagen Inc. (XGN) Stock Price, Analysis & Data
No data available
| Bid | 5.1 |
| Market Cap | 184M |
| Revenue (ttm) | 71.1M |
| Net Income (ttm) | -18.9M |
| 2.10 | |
| -0.82 | |
| n/a | |
| -17.23 | |
| P/B (ttm) | 15.01 |
| P/S (ttm) | 2.58 |
| Earnings Date | Nov 10, 2026 |
| Ask | 8.21 |
| Volume | 138,170 |
| Avg. Volume (20D) | 310,550 |
| Open | 7.40 |
| Previous Close | 7.54 |
| Day's Range | 7.38 - 7.62 |
| 52-Week Range | 2.59 - 12.23 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About XGN
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential ...
Industry Diagnostics & Research
Sector Healthcare
IPO Date Sep 19, 2019
Employees 216
Stock Exchange NasdaqGM
Ticker Symbol XGN
Website https://www.exagen.com
Financial Performance
In 2025, Exagen's revenue was 66.58M, an increase of 19.65% compared to the previous year's 55.64M. Earnings were -19.95M, an increase of 31.99%.
Financial StatementsEarnings Surprise
Exagen has released their quarterly earnings on Aug 4, 2026:
- Revenue of $19.94M misses estimates by $0, with 15.92% YoY growth.
- EPS of -0.11 exceeds estimates by 0.06, with 38.89% YoY growth.
Exagen Inc. is scheduled to release its earnings on Nov 10, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2